Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Shopping Cart 0
countryflagAU
Login

Indivior PLC Ordinary Shares

Healthcare US INDV

33.34USD
0.74(2.27%)

Last update at 2026-03-10T20:00:00Z

Day Range

30.8734.11
LowHigh

52 Week Range

14.3826.50
LowHigh

Fundamentals

  • Previous Close 32.60
  • Market Cap2492.01M
  • Volume4361975
  • P/E Ratio462.00
  • Dividend Yield-%
  • EBITDA267.00M
  • Revenue TTM1124.00M
  • Revenue Per Share TTM8.20
  • Gross Profit TTM 742.00M
  • Diluted EPS TTM0.04

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -95.00000M 190.00M -173.00000M 180.00M
Minority interest - - - -
Net income -53.00000M 205.00M -148.00000M 134.00M
Selling general administrative 763.00M 418.00M 649.00M 395.00M
Selling and marketing expenses - - - -
Gross profit 742.00M 664.00M 550.00M 645.00M
Reconciled depreciation 21.00M 22.00M 26.00M 28.00M
Ebit 212.00M 187.00M 88.00M 202.00M
Ebitda -45.00000M 239.00M -121.00000M 230.00M
Depreciation and amortization - - - -
Non operating income net other - - - -
Operating income -91.00000M 181.00M -156.00000M 178.00M
Other operating expenses -3.00000M -3.00000M -3.00000M -3.00000M
Interest expense 29.00M 27.00M 26.00M 22.00M
Tax provision -42.00000M -15.00000M -25.00000M 46.00M
Interest income 19.00M 4.00M 9.00M 24.00M
Net interest income -10.00000M -23.00000M -17.00000M 2.00M
Extraordinary items - - - -
Non recurring - - - -
Other items - - - -
Income tax expense -42.00000M -15.00000M -25.00000M 46.00M
Total revenue 901.00M 791.00M 647.00M 785.00M
Total operating expenses 992.00M 610.00M 803.00M 607.00M
Cost of revenue 159.00M 127.00M 97.00M 140.00M
Total other income expense net - - - -
Discontinued operations - - - -
Net income from continuing ops -53.00000M 205.00M -148.00000M 134.00M
Net income applicable to common shares -53.00000M 205.00M -148.00000M 134.00M
Preferred stock and other adjustments - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 1954.00M 1769.00M 1832.00M 1531.00M 1652.00M
Intangible assets 232.00M 70.00M 82.00M 62.00M 72.00M
Earning assets - - - - -
Other current assets 434.00M 13.00M 14.00M 33.00M 12.00M
Total liab 1954.00M 1718.00M 1629.00M 1449.00M 1443.00M
Total stockholder equity 0.00000M 51.00M 203.00M 82.00M 209.00M
Deferred long term liab - - - - -
Other current liab 125.00M 391.00M 73.00M 459.00M 570.00M
Common stock - 68.00M 70.00M 73.00M 73.00M
Capital stock 68.00M 68.00M 70.00M 73.00M 73.00M
Retained earnings 1244.00M 1303.00M 1438.00M 1311.00M 1449.00M
Other liab - 433.00M 550.00M 577.00M 417.00M
Good will 5.00M - - - -
Other assets - 257.00M 211.00M 179.00M 113.00M
Cash 316.00M 774.00M 1102.00M 858.00M 1060.00M
Cash and equivalents - - - - -
Total current liabilities 1305.00M 1019.00M 804.00M 599.00M 742.00M
Current deferred revenue - - - - -
Net debt - - - - -
Short term debt - - - - -
Short long term debt 3.00M 3.00M 3.00M 4.00M 4.00M
Short long term debt total - - - - -
Other stockholder equity - -1328.00000M -1312.00000M -1308.00000M -1318.00000M
Property plant equipment - 85.00M 95.00M 103.00M 107.00M
Total current assets 1263.00M 1259.00M 1444.00M 1187.00M 1360.00M
Long term investments - - - - -
Net tangible assets - -19.00000M 121.00M 20.00M 137.00M
Short term investments 94.00M 119.00M - - -
Net receivables 254.00M 225.00M 215.00M 186.00M 192.00M
Long term debt 236.00M 237.00M 239.00M 230.00M 233.00M
Inventory 142.00M 114.00M 95.00M 93.00M 73.00M
Accounts payable 39.00M 36.00M 137.00M 20.00M 39.00M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 9.00M 18.00M 84.00M 82.00M 50.00M
Deferred long term asset charges - - - - -
Non current assets total 691.00M 510.00M 388.00M 344.00M 292.00M
Capital lease obligations 43.00M 37.00M 44.00M 51.00M 56.00M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -218.00000M -218.00000M -218.00000M -218.00000M
Change to liabilities -98.00000M 201.00M -103.00000M -101.00000M
Total cashflows from investing activities -223.00000M -14.00000M -4.00000M -2.00000M
Net borrowings -12.00000M 6.00M -11.00000M -13.00000M
Total cash from financing activities -100.00000M -94.00000M -10.00000M -13.00000M
Change to operating activities 269.00M 269.00M 85.00M -64.00000M
Net income -53.00000M 205.00M -148.00000M 134.00M
Change in cash -328.00000M 244.00M -202.00000M 136.00M
Begin period cash flow 1102.00M 858.00M 1060.00M 924.00M
End period cash flow 774.00M 1102.00M 858.00M 1060.00M
Total cash from operating activities -4.00000M 353.00M -193.00000M 151.00M
Issuance of capital stock 2.00M 1.00M 1.00M 0.00000M
Depreciation 19.00M 19.00M 21.00M 20.00M
Other cashflows from investing activities - - - 1.00M
Dividends paid - - - -
Change to inventory -25.00000M -3.00000M -16.00000M 7.00M
Change to account receivables -21.00000M -25.00000M 15.00M 79.00M
Sale purchase of stock -90.00000M -101.00000M - -
Other cashflows from financing activities - - - -
Change to netincome -97.00000M -47.00000M -52.00000M 68.00M
Capital expenditures 5.00M 4.00M 4.00M 7.00M
Change receivables - - - -
Cash flows other operating - - - -
Exchange rate changes - - - -
Cash and cash equivalents changes - - - -
Change in working capital 125.00M 173.00M -19.00000M -79.00000M
Stock based compensation 16.00M 11.00M 8.00M 3.00M
Other non cash items - - - -
Free cash flow -10.00000M 319.00M -197.00000M 144.00M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
INDV
Indivior PLC Ordinary Shares		 0.74 2.27% 33.34 462.00 - 2.54 47.44 2.32 38.46
ZTS
Zoetis Inc		 -1.87 1.53% 120.49 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR		 0.56 2.23% 25.64 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 -2.64 2.02% 128.01 21.73 14.95 3.16 2.15 3.56 12.82
TAK
Takeda Pharmaceutical Co Ltd ADR		 0.14 0.77% 18.21 32.67 11.53 0.01 0.87 0.02 0.07

Reports Covered

Stock Research & News

View All

Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Indivior PLC Ordinary Shares

10710 Midlothian Turnpike, North Chesterfield, VA, United States, 23235

Key Executives

Name Title Year Born
Mr. Mark Crossley CEO & Executive Director NA
Mr. Ryan Preblick CFO & Executive Director NA
Dr. Christian Heidbreder Chief Scientific Officer NA
Mr. Jason Thompson Vice President of Investor Relations NA
Ms. Cynthia Cetani Chief Integrity & Compliance Officer NA
Mr. Jeffrey W. Burris Chief Legal Officer 1972
Mr. Jon Fogle Chief Human Resources Officer NA
Mr. Richard Simkin Chief Commercial Officer NA
Mr. Hillel West Chief Manufacturing & Supply Officer NA
Mr. Vishal Kalia SVP of US Treatment Access, Support Programs & Business Insights and Chief Impact & Strategy Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.